Market Overview

Par Pharmaceutical Receives Final Approval To Market Tretinoin Capsules

Related PRX
'Spider-Man' Glenn King Hopes His Potential Stroke-Saving Arachnid Molecule Makes It To Market
Endo Bought Par In One Of Biggest Generics M&A Deals Ever: What The Street's Saying

Par Pharmaceutical Companies, Inc. today announced that its operating subsidiary, Anchen Pharmaceuticals, Inc., has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for tretinoin capsules, 10 mg.  Tretinoin capsules is the generic version of Vesanoid^® capsules and is used in the treatment of acute promyelocytic leukemia.  Par expects to begin shipping the product before the end of the month. 

Posted-In: News FDA


Related Articles (PRX)

View Comments and Join the Discussion!